Hudson Canyon Capital Management lowered its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 12.5% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,683 shares of the company’s stock after selling 671 shares during the quarter. Eli Lilly and Company makes up approximately 2.9% of Hudson Canyon Capital Management’s holdings, making the stock its 6th biggest position. Hudson Canyon Capital Management’s holdings in Eli Lilly and Company were worth $4,240,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. D.A. Davidson & CO. raised its holdings in Eli Lilly and Company by 4.9% in the 2nd quarter. D.A. Davidson & CO. now owns 43,054 shares of the company’s stock worth $38,981,000 after purchasing an additional 2,027 shares during the period. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH increased its position in Eli Lilly and Company by 8.3% in the second quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH now owns 63,161 shares of the company’s stock worth $57,185,000 after buying an additional 4,819 shares in the last quarter. Drive Wealth Management LLC raised its stake in shares of Eli Lilly and Company by 2.8% in the second quarter. Drive Wealth Management LLC now owns 2,242 shares of the company’s stock worth $2,029,000 after buying an additional 62 shares during the period. JPL Wealth Management LLC lifted its position in shares of Eli Lilly and Company by 38.1% during the 2nd quarter. JPL Wealth Management LLC now owns 783 shares of the company’s stock valued at $709,000 after buying an additional 216 shares in the last quarter. Finally, Massachusetts Wealth Management grew its stake in shares of Eli Lilly and Company by 35.1% during the 2nd quarter. Massachusetts Wealth Management now owns 2,215 shares of the company’s stock valued at $2,005,000 after acquiring an additional 575 shares during the period. Institutional investors own 82.53% of the company’s stock.
Insider Buying and Selling at Eli Lilly and Company
In related news, major shareholder Lilly Endowment Inc sold 20,383 shares of Eli Lilly and Company stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $836.32, for a total transaction of $17,046,710.56. Following the transaction, the insider now directly owns 98,188,427 shares of the company’s stock, valued at $82,116,945,268.64. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders sold a total of 897,283 shares of company stock valued at $805,651,743 in the last ninety days. Corporate insiders own 0.13% of the company’s stock.
Analyst Ratings Changes
Eli Lilly and Company Price Performance
Shares of LLY stock opened at $960.02 on Monday. The stock has a 50 day moving average price of $892.64 and a 200 day moving average price of $822.54. Eli Lilly and Company has a 52-week low of $516.57 and a 52-week high of $972.53. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The firm has a market capitalization of $912.43 billion, a P/E ratio of 141.39, a P/E/G ratio of 2.91 and a beta of 0.41.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping the consensus estimate of $2.64 by $1.28. The company had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. As a group, sell-side analysts predict that Eli Lilly and Company will post 16.51 earnings per share for the current year.
Eli Lilly and Company Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 annualized dividend and a yield of 0.54%. Eli Lilly and Company’s payout ratio is currently 76.58%.
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
See Also
- Five stocks we like better than Eli Lilly and Company
- How to Capture the Benefits of Dividend Increases
- Autodesk Stock: Analysts’ Top AI Pick You Shouldn’t Overlook
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Hidden Opportunities in Li Auto’s Tough Quarter You Can’t Miss
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Don’t Overlook Campbell Soup: Here’s What Could Drive Its Stock
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.